{"result": "(\"entity\"<|>CARCINOMA SUPRARRENAL<|>EVENT<|>Carcinoma suprarrenal is a rare primary cancer with an incidence of 1 in 1,000,000 inhabitants per year, affecting women more frequently than men, typically diagnosed between the ages of 40 and 50.)\n##\n(\"entity\"<|>HIPERPLASIA SUPRARRENAL CONGÉNITA<|>EVENT<|>Congenital adrenal hyperplasia is a genetic disorder with autosomal recessive inheritance affecting enzymes involved in cortisol synthesis, leading to hormonal imbalances.)\n##\n(\"entity\"<|>MITOTANO<|>ORGANIZATION<|>Mitotane is a medication indicated for symptomatic treatment of advanced, inoperable, metastatic, or recurrent adrenal cortex carcinoma, and may also be used as an adjuvant treatment in high-risk patients.)\n##\n(\"entity\"<|>ACTH<|>ORGANIZATION<|>Adrenocorticotropic hormone (ACTH) is a hormone that stimulates the adrenal glands, and its elevated levels can lead to adrenal hyperplasia in congenital adrenal hyperplasia cases.)\n##\n(\"entity\"<|>GLUCOCORTICOIDES<|>ORGANIZATION<|>Glucocorticoids are steroid hormones that play a role in the treatment of adrenal disorders, including congenital adrenal hyperplasia and adrenal carcinoma.)\n##\n(\"entity\"<|>HOMBRES<|>PERSON<|>Men are generally diagnosed with adrenal carcinoma at an older age compared to women, with a lower incidence rate.)\n##\n(\"entity\"<|>MUJERES<|>PERSON<|>Women are more frequently affected by adrenal carcinoma and congenital adrenal hyperplasia, with specific treatment recommendations during pregnancy.)\n##\n(\"relationship\"<|>CARCINOMA SUPRARRENAL<|>MITOTANO<|>Mitotano is used for the treatment of advanced adrenal carcinoma, indicating a direct relationship between the drug and the disease<|>8)\n##\n(\"relationship\"<|>HIPERPLASIA SUPRARRENAL CONGÉNITA<|>ACTH<|>Elevated ACTH levels are a consequence of cortisol deficiency in congenital adrenal hyperplasia, linking the hormone to the condition<|>7)\n##\n(\"relationship\"<|>MUJERES<|>HIPERPLASIA SUPRARRENAL CONGÉNITA<|>Women with congenital adrenal hyperplasia require specific treatment during pregnancy, highlighting the relationship between gender and the condition<|>6)\n##\n(\"relationship\"<|>MUJERES<|>CARCINOMA SUPRARRENAL<|>Women are more frequently diagnosed with adrenal carcinoma, establishing a connection between gender and the disease<|>5)\n##\n(\"relationship\"<|>GLUCOCORTICOIDES<|>MUJERES<|>Glucocorticoids are recommended for women with congenital adrenal hyperplasia who are planning pregnancy, indicating a treatment relationship<|>6)\n##\n(\"relationship\"<|>GLUCOCORTICOIDES<|>CARCINOMA SUPRARRENAL<|>Glucocorticoids are used in the management of adrenal carcinoma, linking the treatment to the disease<|>5)\n##\n(\"relationship\"<|>HOMBRES<|>CARCINOMA SUPRARRENAL<|>Men are diagnosed with adrenal carcinoma at a later age, establishing a demographic relationship with the disease<|>4)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 42  Indique qué es falso en el carcinoma suprarrenal:                                                                                5.7 Hiperplasia suprarrenal congénita\n         A. Son más frecuentes en mujeres.\n         B. Son más frecuentes los tumores con aumento de la producción hormonal.                                                                   Con respecto al manejo de las mujeres con hiperplasia suprarrenal congénita por\n         C. Cuando tienen producción hormonal, de más frecuente a menos frecuente, la producción                                             43     déficit de 21-hidroxilasa, señale la respuesta falsa:\n             hormonal corresponde a: andrógenos, glucocorticoides, aldosterona.\n         D.  El tratamiento con mitotano, en niveles terapéuticos, reduce el crecimiento tumoral                                                    A. En mujeres con formas no clásicas que planifican embarazo se recomienda tratamiento\n             y la hipersecreción hormonal.                                                                                                              con glucocorticoides si existe historia previa de abortos.\n                                                                                                                                                    B. Durante el embarazo en mujeres con formas clásicas se recomienda tratamiento con\n         COMENTARIO                                                                                                                                     glucocorticoides que no atraviesan la placenta.\n                                                                                                                                                    C. En mujeres con formas clásicas se recomienda duplicar las dosis de hidrocortisona/\n         El carcinoma suprarrenal primario es infrecuente, con una incidencia de 1:1.000.000 de ha-                                                     prednisolona y fludrocortisona pregestacionales en el momento de confirmar embarazo.\n         bitantes por año. Las mujeres suelen verse afectadas con más frecuencia que los hombres                                                    D.  En mujeres con formas clásicas gestantes se recomienda dosis de estrés de\n         (2,5:1). La media de edad del comienzo es de 40 a 50 años, aunque los hombres tienden a                                                        glucocorticoides durante el parto.\n         una mayor edad en el momento del diagnóstico. El 80% de los tumores son funcionales, y\n         lo más frecuente es que segreguen glucocorticoides solamente (45%), glucocorticoides\n         y andrógenos (45%) o solo andrógenos (10%).                                                                                                COMENTARIO\n         La cirugía ofrece la única opción de curación a los pacientes con enfermedad localizada.                                                   La hiperplasia suprarrenal congénita es una enfermedad genética con herencia autosó-\n         El mitotano está indicado en ficha técnica para el tratamiento sintomático del carcinoma avan-                                             mica recesiva que afecta a cualquiera de las enzimas implicadas en la síntesis del cortisol.\n         zado de la corteza suprarrenal inextirpable, metastásico o recidivante. También se ha sugerido                                             El defecto de cortisol provoca un aumento en los niveles de ACTH y la consiguiente hiper-\n         su utilización adyuvante a la cirugía en pacientes con alto riesgo de recurrencia como serían la                                           plasia de la glándula.\n         enfermedad con alto grado histológico (Ki67 > 10%; más de 20 mitosis por 50 campos, rotura                                                 La hiperplasia suprarrenal congénita por déficit de 21-hidroxilasa (CYP21A2) supone el\n         del tumor intraoperatoria y algunos tumores de gran tamaño y bajo grado histológico, pero con                                              90% de los casos. Este defecto provoca una conversión defectuosa de 17-α-hidroxiproges-\n         invasión capsular o vascular.                                                                                                              terona en 11-desoxicortisol (en la vía de síntesis del cortisol), y de la progesterona a desoxi-\n         El mitotano tiene actividad citotóxica sobre la corteza suprarrenal, aunque al parecer tam-                                                corticosterona (DOCA) (en la vía de síntesis de la aldosterona). Al no existir ningún bloqueo\n         bién puede causar inhibición suprarrenal sin destrucción celular, e induce un estado de                                                    sobre la vía de síntesis de los andrógenos suprarrenales, la hiperplasia de la suprarrenal\n         insuficiencia suprarrenal que deberá ser tratada y que puede precisar dosis de sustitución                                                 por el estímulo de la ACTH dará lugar a un aumento en los niveles de los andrógenos su-\n         de glucocorticoides más altas de lo habitual por el efecto sobre el metabolismo periférico                                                 prarrenales, lo que determina parte de la clínica asociada al trastorno.\n         del cortisol.                                                                                                                              Se recomienda el tratamiento con un glucocorticoide que se inactive a nivel placentario\n         Se considera que la zona glomerular, responsable de la síntesis de los mineralocorticoides,                                                (glucocorticoides que no atraviesan la placenta) para aquellas mujeres con hiperplasia su-\n         es más resistente al efecto adrenolítico del mitotano.                                                                                     prarrenal congénita no clásica por déficit de 21-hidroxilasa que desean gestación y presen-\n                                                                                                                                                    tan infertilidad o abort\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}